 |
104 Diseases |  |
139 Trials |
|
139 Trials |  |
6449 News |  |
| «12...7778798081828384858687...9091» |
- ||| Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
Enrollment change, Combination therapy: ROAR: Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers (clinicaltrials.gov) - May 8, 2017
P2, N=225, Recruiting, Sponsor: GlaxoSmithKline
N=135 --> 225
- ||| Zykadia (ceritinib) / Novartis, Mekinist (trametinib) / Novartis, BeiGene
Trial initiation date, Metastases: Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - May 8, 2017
P1/2, N=69, Not yet recruiting, Sponsor: University of California, San Francisco
N=135 --> 225 Initiation date: Mar 2017 --> Jun 2017
- | Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
Enrollment closed: Neo Combi: Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma (clinicaltrials.gov) - May 4, 2017
P2, N=35, Active, not recruiting, Sponsor: Melanoma Institute Australia
Initiation date: Mar 2017 --> Jun 2017 Recruiting --> Active, not recruiting
- ||| Mekinist (trametinib) / Novartis, BeiGene, Kisqali (ribociclib) / Novartis
Enrollment change, Combination therapy, Metastases: Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors (clinicaltrials.gov) - May 3, 2017
P1/2, N=124, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting N=84 --> 124
- | Mekinist (trametinib) / Novartis, BeiGene, uprosertib (LAE003) / Laekna Therap
Trial primary completion date: Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - May 1, 2017
P2, N=74, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=84 --> 124 Trial primary completion date: Jan 2017 --> Dec 2017
- | Mekinist (trametinib) / Novartis, BeiGene
Trial primary completion date: Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction (clinicaltrials.gov) - Apr 28, 2017
P1, N=68, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2017 --> Dec 2017 Trial primary completion date: Jan 2017 --> Sep 2017
- navtemadlin (KRT-232) / Kartos Therap
Enrollment closed, Enrollment change, Combination therapy: A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 28, 2017
P1b, N=36, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Jan 2017 --> Sep 2017 Recruiting --> Active, not recruiting | N=130 --> 36
- | Mekinist (trametinib) / Novartis, BeiGene, uprosertib (LAE003) / Laekna Therap
Enrollment change, Combination therapy: Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer (clinicaltrials.gov) - Apr 26, 2017
P2, N=26, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=130 --> 36 N=148 --> 26
- | Mekinist (trametinib) / Novartis, BeiGene
Metastases: Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 21, 2017
P2, N=53, Recruiting, Sponsor: National Cancer Institute (NCI)
N=148 --> 26 Trial primary completion date: Feb 2017 --> Oct 2020
- ||| Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
New P1 trial: A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 30, 2017
P1, N=60, Not yet recruiting, Sponsor: Massachusetts General Hospital
- |||||| Mekinist (trametinib) / Novartis, BeiGene, spartalizumab (PDR001) / Novartis, Tafinlar (dabrafenib) / Novartis
Enrollment open, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: COMBI-i: A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma (clinicaltrials.gov) - Mar 28, 2017
P3, N=538, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Feb 2017 --> Oct 2020 Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2019 --> Dec 2020
- Ojjaara (momelotinib) / GSK
Trial termination, Metastases: Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase (clinicaltrials.gov) - Mar 27, 2017
P1b, N=21, Terminated, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2019 --> Dec 2020 Active, not recruiting --> Terminated
- | Biomarker, Enrollment change, BRCA Biomarker, PD(L)-1 Biomarker, Metastases: NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (clinicaltrials.gov) - Mar 24, 2017
P2, N=6452, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated N=3000 --> 6452
- || Keytruda (pembrolizumab) / Merck (MSD)
Trial primary completion date, PD(L)-1 Biomarker, Metastases: A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) (clinicaltrials.gov) - Mar 23, 2017
P1/2, N=219, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=3000 --> 6452 Trial primary completion date: Sep 2018 --> Jul 2021
- | Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
Trial primary completion date: Neo Combi: Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma (clinicaltrials.gov) - Mar 23, 2017
P2, N=35, Recruiting, Sponsor: Melanoma Institute Australia
Trial primary completion date: Sep 2018 --> Jul 2021 Trial primary completion date: Feb 2017 --> Jun 2017
- | Trial initiation date, PARP Biomarker, Metastases: MatchMel: Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (clinicaltrials.gov) - Mar 23, 2017
P4, N=1000, Not yet recruiting, Sponsor: Melanoma Institute Australia
Trial primary completion date: Feb 2017 --> Jun 2017 Initiation date: Mar 2017 --> Jun 2017
- ||||| Mekinist (trametinib) / Novartis, BeiGene, Vectibix (panitumumab) / Amgen
New P2 trial, Combination therapy, Metastases: Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer (clinicaltrials.gov) - Mar 22, 2017
P2, N=84, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- ||||| Zykadia (ceritinib) / Novartis, Mekinist (trametinib) / Novartis, BeiGene
New P1/2 trial, Metastases: Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Mar 22, 2017
P1/2, N=69, Not yet recruiting, Sponsor: University of California, San Francisco
- | New P1 trial, Combination therapy, Metastases: Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma (clinicaltrials.gov) - Mar 21, 2017
P1b, N=20, Not yet recruiting, Sponsor: West Cancer Center
- Mekinist (trametinib) / Novartis, BeiGene
New trial, Combination therapy: Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer (clinicaltrials.gov) - Mar 21, 2017
P=N/A, N=12, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- || naporafenib (ERAS-254) / Erasca
Trial primary completion date, Combination therapy, Metastases: A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma (clinicaltrials.gov) - Mar 19, 2017
P1, N=75, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Mar 2017 --> Jun 2017 Trial primary completion date: Dec 2019 --> Sep 2017
- | Mekinist (trametinib) / Novartis
Journal: Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. (Pubmed Central) - Mar 17, 2017
Combination strategies based on a better understanding of the hierarchical role of mutations and signaling in myeloid malignancies are likely to improve the response rate and duration. Cancer 2016.
- | Mekinist (trametinib) / Novartis, BeiGene
Trial primary completion date, Combination therapy, Surgery: Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Mar 13, 2017
P1, N=30, Recruiting, Sponsor: National Cancer Institute (NCI)
Cancer 2016. Trial primary completion date: Dec 2016 --> Jul 2018
- Enrollment change, Trial withdrawal, Combination therapy, Stroma, Metastases: SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor) (clinicaltrials.gov) - Mar 13, 2017
P2, N=0, Withdrawn, Sponsor: Sarcoma Alliance for Research through Collaboration
Trial primary completion date: Dec 2016 --> Jul 2018 N=45 --> 0 | Not yet recruiting --> Withdrawn
- | Mekinist (trametinib) / Novartis, BeiGene
New P1/2 trial: A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib (clinicaltrials.gov) - Mar 10, 2017
P1/2, N=30, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- || Mekinist (trametinib) / Novartis, BeiGene
Phase classification: Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 (clinicaltrials.gov) - Mar 8, 2017
P, N=15, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
N=45 --> 0 | Not yet recruiting --> Withdrawn Phase classification: P=N/A --> P
- | Mekinist (trametinib) / Novartis, BeiGene, uprosertib (LAE003) / Laekna Therap
Enrollment closed, Combination therapy, Metastases: Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma (clinicaltrials.gov) - Mar 8, 2017
P2, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Phase classification: P=N/A --> P Recruiting --> Active, not recruiting
- | Mekinist (trametinib) / Novartis, BeiGene, uprosertib (LAE003) / Laekna Therap
Enrollment closed, Combination therapy, Metastases: Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov) - Mar 6, 2017
P2, N=41, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Enrollment closed, Trial primary completion date, Metastases: LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations (clinicaltrials.gov) - Mar 6, 2017
P2, N=17, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Apr 2017
- | Mekinist (trametinib) / Novartis, Koselugo (selumetinib) / Merck (MSD), AstraZeneca
Journal: Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review. (Pubmed Central) - Mar 5, 2017
This has translated into a multitude of important preclinical studies and clinical trials that are currently underway to find effective therapeutic drugs for KRAS mutant lung cancer. Ultimately, better therapeutics need to be engineered to arrive at RAS-driven precision medicine.
- | Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
Phase classification, Trial initiation date, Trial primary completion date, IO biomarker: Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma (clinicaltrials.gov) - Mar 3, 2017
P2, N=17, Not yet recruiting, Sponsor: Stanford University
Ultimately, better therapeutics need to be engineered to arrive at RAS-driven precision medicine. Phase classification: P=N/A --> P2 | Initiation date: Oct 2016 --> Apr 2017 | Trial primary completion date: Dec 2018 --> Jun 2019
- ||| naporafenib (ERAS-254) / Erasca
Enrollment open, Enrollment change, Combination therapy, Metastases: A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma (clinicaltrials.gov) - Mar 3, 2017
P1, N=75, Recruiting, Sponsor: Novartis Pharmaceuticals
Phase classification: P=N/A --> P2 | Initiation date: Oct 2016 --> Apr 2017 | Trial primary completion date: Dec 2018 --> Jun 2019 Not yet recruiting --> Recruiting | N=100 --> 75
- ||| Ibrance (palbociclib) / Pfizer, Mekinist (trametinib) / Novartis, BeiGene, Nerlynx (neratinib) / Puma
New P1 trial, Combination therapy, Metastases: NCI-2018-01218: Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation (clinicaltrials.gov) - Feb 27, 2017
P1, N=120, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | Journal: Treatment of ameloblastoma and ameloblastic carcinoma with radiotherapy. (Pubmed Central) - Feb 25, 2017
For patients with local recurrence or inadequate margins after surgery, adjuvant radiotherapy provides the potential for disease control. In the setting of metastatic disease, targeted therapies may provide an additional opportunity for salvage.
- || Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
Trial primary completion date, Combination therapy: Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma (clinicaltrials.gov) - Feb 24, 2017
P2, N=65, Recruiting, Sponsor: GlaxoSmithKline
In the setting of metastatic disease, targeted therapies may provide an additional opportunity for salvage. Trial primary completion date: Nov 2017 --> Jun 2018
- || Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
Trial primary completion date, Combination therapy: ROAR: Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers (clinicaltrials.gov) - Feb 24, 2017
P2, N=135, Recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Nov 2017 --> Jun 2018 Trial primary completion date: Jun 2019 --> Jun 2020
- ||| Trial completion: DEIS: Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain (clinicaltrials.gov) - Feb 24, 2017
P=N/A, N=135, Completed, Sponsor: Grupo Espa
Trial primary completion date: Jun 2019 --> Jun 2020 Active, not recruiting --> Completed
- ||| emibetuzumab (LY2875358) / Eli Lilly, Innovent Biologics
Trial completion, Metastases: A Study of LY2875358 in Participants With Advanced Cancer (clinicaltrials.gov) - Feb 15, 2017
P1, N=117, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis
Trial initiation date, Trial primary completion date, Combination therapy: CDRB436G2201: Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors (clinicaltrials.gov) - Feb 13, 2017
P2, N=30, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Initiation date: Apr 2017 --> Jul 2017 | Trial primary completion date: May 2020 --> Apr 2022
- veliparib (ABT-888) / AbbVie, Mekinist (trametinib) / Novartis, BeiGene, adavosertib (AZD1775) / AstraZeneca
Phase classification, PARP Biomarker, Metastases: MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations (clinicaltrials.gov) - Feb 3, 2017
P2, N=700, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Apr 2017 --> Jul 2017 | Trial primary completion date: May 2020 --> Apr 2022 Phase classification: P=N/A --> P2
- |||| Enrollment open, Metastases: BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma (clinicaltrials.gov) - Feb 1, 2017
P1/2, N=92, Recruiting, Sponsor: Haukeland University Hospital
Phase classification: P=N/A --> P2 Not yet recruiting --> Recruiting
- Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, onalespib (AT13387) / Otsuka
Trial primary completion date, Combination therapy, Surgery, Metastases: Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jan 31, 2017
P1, N=32, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Jun 2018
- Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
Trial primary completion date: Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer (clinicaltrials.gov) - Jan 30, 2017
P2, N=52, Active, not recruiting, Sponsor: Manisha Shah
Trial primary completion date: Dec 2016 --> Jun 2018 Trial primary completion date: Sep 2017 --> Dec 2017
- Mekinist (trametinib) / Novartis, BeiGene
Enrollment change, Trial withdrawal: Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours (clinicaltrials.gov) - Jan 26, 2017
P1, N=0, Withdrawn, Sponsor: GlaxoSmithKline
Trial primary completion date: Sep 2017 --> Dec 2017 N=10 --> 0 | Not yet recruiting --> Withdrawn
- Mekinist (trametinib) / Novartis, BeiGene
Trial primary completion date, Combination therapy, Metastases: Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer (clinicaltrials.gov) - Jan 24, 2017
P1a/1b, N=34, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
N=10 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Mar 2017 --> Dec 2017
- Biomarker, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker, Surgery, Metastases: Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jan 23, 2017
P1, N=40, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Mar 2017 --> Dec 2017 Trial primary completion date: Jun 2016 --> Jan 2018
- ||| Imfinzi (durvalumab) / AstraZeneca
Enrollment change, Combination therapy, PD(L)-1 Biomarker, Metastases: Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone (clinicaltrials.gov) - Jan 23, 2017
P1/2, N=101, Active, not recruiting, Sponsor: MedImmune LLC
Trial primary completion date: Jun 2016 --> Jan 2018 N=69 --> 101
- Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis
Surgery: Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Jan 19, 2017
P2, N=280, Recruiting, Sponsor: National Cancer Institute (NCI)
N=69 --> 101 Trial primary completion date: Dec 2016 --> Jun 2020
- Mekinist (trametinib) / Novartis, BeiGene
Enrollment change, Surgery, Metastases: SWOG-S1310: Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery (clinicaltrials.gov) - Jan 6, 2017
P2, N=52, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2016 --> Jun 2020 N=89 --> 52
- Mekinist (trametinib) / Novartis, BeiGene
Trial primary completion date: A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors (clinicaltrials.gov) - Jan 5, 2017
P1, N=24, Recruiting, Sponsor: Novartis Pharmaceuticals
N=89 --> 52 Trial primary completion date: Jun 2018 --> Oct 2018